← Back to headlines
Tarsus Projects $670M–$700M 2026 Sales, XDEMVY Eyes $2B+ Potential
Tarsus expects 2026 sales between $670 million and $700 million, with its drug XDEMVY projected to reach over $2 billion in potential sales as its pipeline advances.
24 Feb, 11:16 — 24 Feb, 11:16
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Dutch Financial Institutions Aim to Reduce Dependence on US Tech Giants
19m ago
AI's Impact on Productivity and Federal Reserve Interest Rates
20m ago
Think You Can Retire Comfortably on $1 Million? Here's Why You May Need a New Plan.
26m ago
Europe Considers Reducing Reliance on Visa and Mastercard
29m ago